Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News How do Vutrisiran’s HELIOS-B results compare with historical standards in ATTR-CM treatment? Alnylam’s vutrisiran reduces cardiovascular mortality and urgent heart failure visits in ATTR-CM, reinforcing AMVUTTRA’s first-line potential. Read key data now. byPallavi MadhirajuMay 18, 2025